-
Kessler, R. C. et coll. Prévalence à douze mois et au cours de la vie et risque morbide à vie d’anxiété et de troubles de l’humeur aux États-Unis. J. Méthodes Psychiatr. Rés. 21, 169-184 (2012).
Article PubMed PubMed Central Google Scholar
-
Katzman, M. A. et coll. Lignes directrices de pratique clinique canadiennes pour la prise en charge de l’anxiété, du stress post-traumatique et des troubles obsessionnels compulsifs. BMC Psychiatry 14, S1 (2014).
Article PubMed PubMed Central Google Scholar
-
Fava, M. et al. Une étude transversale de la prévalence des symptômes cognitifs et physiques pendant le traitement antidépresseur à long terme. J. Clin. Psychiatry 67, 1754-1759 (2006).
Article PubMed Google Scholar
-
Springer, K. S., Levy, H. C. & Tolin, D. F. Remission in CBT for adult anxiety disorders: a meta-analysis. Clin. Psychol. Rev. 61, 1-8 (2018).
Article PubMed Google Scholar
-
Kroenke, K. et al. Troubles anxieux en soins primaires : prévalence, déficience, comorbidité et détection. Ann. Intern. Med. 146, 317 (2007).
Article PubMed Google Scholar
-
Melas, P. A. et al. Le cannabidiol comme traitement potentiel de l’anxiété et des troubles de l’humeur: cibles moléculaires et connaissances épigénétiques issues de la recherche préclinique. Int. J. Mol. Sci. 22, 1863 (2021).
Article CAS PubMed PubMed Central Google Scholar
-
Stanciu, C. N. et coll. Preuves de l’utilisation des cannabinoïdes dans les troubles de l’humeur, les troubles anxieux et le SSPT: une revue systématique. Psychiatr. 72, 429 à 436 (2021).
Article PubMed PubMed Central Google Scholar
-
Zuardi, A. W. et coll. Action du cannabidiol sur l’anxiété et d’autres effets produits par le Δ9-THC chez des sujets normaux. Psychopharmacology (Berl) 76, 245-250 (1982).
Article CAS Google Scholar
-
Zuardi, A. W. et coll. Effets de l’ipsapirone et du cannabidiol sur l’anxiété expérimentale humaine. J. Psychopharmacol. Oxf. 7, 82-88 (1993).
Article CAS Google Scholar
-
Crippa, J. A. S. et coll. Base neurale des effets anxiolytiques du cannabidiol (CBD) dans le trouble d’anxiété sociale généralisée: un rapport préliminaire. J. Psychopharmacol. (Bœuf) 25, 121-130 (2011).
Article CAS Google Scholar
-
Bergamaschi, M. M. et al. Le cannabidiol réduit l’anxiété induite par la prise de parole en public simulée chez les patients souffrant de phobie sociale naïfs de traitement. Neuropsychopharmacology 36, 1219-1226 (2011).
Article CAS PubMed PubMed Central Google Scholar
-
Masataka N. Effets anxiolytiques du traitement répété au cannabidiol chez les adolescents souffrant de troubles d’anxiété sociale. Avant. Psychol. 0. https://doi.org/10.3389/fpsyg.2019.02466 (2019).
-
Gallily, R., Yekhtin, Z. & Hanuš, L. O. Surmonter la dose-réponse en forme de cloche du cannabidiol en utilisant de l’extrait de cannabis enrichi en cannabidiol. Pharmacol. Pharm. 06, 75-85 (2015).
Article Google Scholar
-
Pamplona, F. A., da Silva, L. R. & Coan, A. C. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Avant. Neurol. 9, 759 (2018).
Article PubMed PubMed Central Google Scholar
-
Russo, E. B. Les arguments en faveur de l’effet d’entourage et de la sélection conventionnelle du cannabis clinique : pas de « souche », pas de gain. Devant. Plant Sci. 9, 1969 (2018).
Article PubMed Google Scholar
-
Gruber, S. A. et al. Splendor in the Grass? A pilot study assessing the impact of medical marijuana on executive function. Front. Pharmacol. 7, 355 (2016).
Article PubMed PubMed Central Google Scholar
-
Gruber, S. A. et al. The grass might be greener: medical marijuana patients exhibit altered brain activity and improved executive function after 3 months of treatment. Front. Pharmacol. 8, 983 (2018).
Article PubMed PubMed Central Google Scholar
-
Sagar, K. A. et al. An observational, longitudinal study of cognition in medical cannabis patients over the course of 12 months of treatment: preliminary results. J. Int. Neuropsychol. Soc. 27, 648–660 (2021).
Article PubMed Google Scholar
-
Sagar, K. A. & Gruber, S. A. Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research. Int. Rev. Psychiatry Abingdon Engl 30, 251–267 (2018).
Article Google Scholar
-
Beck A. T. BAI, Beck Anxiety Inventory: Manual. (Psychological Corporation: San Antonio; 1990).
-
Norman, S. B. et al. Development and validation of an overall anxiety severity and impairment scale (OASIS). Depress Anxiety 23, 245–249 (2006).
Article PubMed Google Scholar
-
Robinson, S. M. et al. Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol. Addict. Behav. 28, 154–162 (2014).
Article PubMed Google Scholar
-
Dahlgren, M. K. et al. Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial. JAMA Psychiatry 78, 335–337 (2021).
Article PubMed Google Scholar
-
Spielberger, C. D., Gorsuch, R. L. & Lushene, R. E. Manual for the State-Trait Anxiety Inventory. (Consulting Psychologists Press: Polo Alto, CA; 1970).
-
Hamilton, M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32, 50–55 (1959).
Article CAS PubMed Google Scholar
-
Kamper, S. J., Maher, C. G. & Mackay, G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J. Man. Manip. Ther. 17, 163–170 (2009).
Article PubMed PubMed Central Google Scholar
-
Beck, A. T. et al. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561–571 (1961).
Article CAS PubMed Google Scholar
-
Pollock, V. et al. Profile of mood states: the factors and their physiological correlates. J. Nerv. Ment. Dis. 167, 612–614 (1979).
Article CAS PubMed Google Scholar
-
Watson, D., Clark, L. A. & Tellegen, A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J. Pers. Soc. Psychol. 54, 1063–1070 (1988).
Article CAS PubMed Google Scholar
-
Beck, A. T. et al. The measurement of pessimism: the hopelessness scale. J. Consult Clin. Psychol. 42, 861–865 (1974).
Article CAS PubMed Google Scholar
-
Beck, A. T. BSI, Beck Scale for Suicide Ideation: Manual. (Psychological Corporation; 1991).
-
Buysse, D. J. et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213 (1989).
Article CAS PubMed Google Scholar
-
McGahuey, C. A. et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther. 26, 25–40 (2000).
Article CAS PubMed Google Scholar
-
Ware, J. E. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med. Care 30, 473–483 (1992).
Article PubMed Google Scholar
-
Lezak, M. D. et al. Neuropsychological Assessments. 5th ed. (Oxford University Press: New York, NY; 2012).
-
Heaton, R. K. & PAR Staff. Wisconsin Card Sorting Test: Computer Version 4. n.d.
-
Bush, G. & Shin, L. M. The multi-source interference task: an FMRI task that reliably activates the cingulo-frontal-parietal cognitive/attention network. Nat. Protoc. 1, 308–313 (2006).
Article PubMed Google Scholar
-
Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Article PubMed Google Scholar
-
Harris, P. A. et al. The REDCap Consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
Article PubMed PubMed Central Google Scholar
-
Torrealday, O. et al. Validation of the marijuana effect expectancy questionnaire-brief. J. Child Adolesc. Subst. Abuse 17, 1–17 (2008).
Article CAS PubMed PubMed Central Google Scholar
-
Johnco, C. J. et al. Refining clinical judgment of treatment response and symptom remission identification in childhood anxiety using a signal detection analysis on the pediatric anxiety rating scale. J. Child Adolesc. Psychopharmacol. 25, 674–683 (2015).
Article PubMed PubMed Central Google Scholar
-
Johnco, C. et al. Defining treatment response and symptom remission for anxiety disorders in pediatric autism spectrum disorders using the pediatric anxiety rating scale. J. Autism Dev. Disord. 45, 3232–3242 (2015).
Article PubMed PubMed Central Google Scholar
-
Sagar, K. et al. Assessing cannabis use disorder in medical cannabis patients: interim analyses from an observational, longitudinal study. Cannabis 4, 47–59 (2021).
Article Google Scholar
-
Eysenck, M. W. et al. Anxiety and cognitive performance: attentional control theory. Emotion 7, 336–353 (2007).
Article PubMed Google Scholar
-
Morton, V. & Torgerson, D. J. Regression to the mean: treatment effect without the intervention. J. Eval. Clin. Pract. 11, 59–65 (2005).
Article PubMed Google Scholar
-
Asnaani, A. et al. A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J. Nerv. Ment. Dis. 198, 551–555 (2010).
Article PubMed PubMed Central Google Scholar
-
Vilsaint, C. L. et al. Racial/ethnic differences in 12-month prevalence and persistence of mood, anxiety, and substance use disorders: variation by nativity and socioeconomic status. Compr. Psychiatry 89, 52–60 (2019).
Article PubMed Google Scholar
-
Cooper, Z. D. & Craft, R. M. Effets dépendants du sexe du cannabis et des cannabinoïdes: une perspective translationnelle. Neuropsychopharmacology 43, 34-51 (2018).
Article CAS PubMed Google Scholar
-
Sholler, D. J. et coll. Différences entre les sexes dans les effets aigus du cannabis oral et vaporisé chez les adultes en bonne santé. Toxicomane. Biol. 26, e12968 (2021).
Article CAS PubMed Google Scholar
-
Liu, J. et coll. Expression des transcrits isozymes du cytochrome P450 et activités dans le foie humain. Xenobiotica 51, 279-286 (2021).
Article CAS PubMed Google Scholar
-
Bansal, S. et al. Prédire le potentiel des cannabinoïdes à précipiter les interactions médicamenteuses pharmacocinétiques via l’inhibition réversible ou l’inactivation des cytochromes majeurs P450. Médicament Metab. Dispose. 48, 1008-1017 (2020).
Article CAS PubMed PubMed Central Google Scholar
-
Doohan, P. T. et coll. Interactions des cannabinoïdes avec le métabolisme des médicaments du cytochrome P450: une caractérisation à spectre complet. Am. Assoc. Pharm. Sci. J. 23, 91 (2021).
CAS Google Scholar